title: Effect of subchronic administration of tachykinin antagonists on response of guinea-pigs to mild and severe stress.
abstract: The effects of subchronic subcutaneous treatment with tachykinin receptor antagonists over nine days on the repeated mild stress response induced by daily subcutaneous injections and on the severe acute stress induced by morphine withdrawal were investigated in guinea-pigs. The NK(1) receptor antagonist, L733,060, 0.25mg/kg, significantly increased locomotor activity of guinea-pigs compared with animals subjected to repeated injection of the inactive enantiomer, but inhibited Fos-like immunoreactivity (Fos-LI) in the hypothalamus. In animals subjected to the acute severe stress of naltrexone-induced morphine withdrawal, treatment with the NK(1) antagonist, L733,060, produced reductions in Fos-LI in the spinal dorsal horn, whereas those treated with the NK(3) antagonist, SSR146,977, 0.3mg/kg, had reduced Fos-LI in the dorsal horn, adrenal medulla, nucleus accumbens, ventral tegmental area and periaqueductal grey. Those animals treated with both NK(1) and NK(3) antagonists also had reduced Fos-LI in the amygdala and paraventricular nucleus of the thalamus. It was concluded that the NK(1) antagonist reduced the hypothalamic response to mild stress but the NK(3) antagonist was more effective in reducing the severe stress response to morphine withdrawal. Furthermore, combination of NK(1) and NK(3) antagonists was more effective than either antagonist in reducing the Fos-LI response to morphine withdrawal.
authors.forename: Wayne
authors.initials: W
authors.lastname: Anderson
authors.forename: Penny
authors.initials: P
authors.lastname: Newson
authors.forename: Maria
authors.initials: M
authors.lastname: Skeri
authors.forename: Norma
authors.initials: N
authors.lastname: Janssen
authors.forename: Stephen
authors.initials: S
authors.lastname: Milne
authors.forename: Jane
authors.initials: J
authors.lastname: Yip
authors.forename: Sebastian
authors.initials: S
authors.lastname: Jungnickel
authors.forename: Ann
authors.initials: A
authors.lastname: Lynch-Frame
authors.forename: Loris A
authors.initials: LA
authors.lastname: Chahl
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006168:Guinea Pigs; D055104:Infusions, Subcutaneous; D008297:Male; D008782:Methylurea Compounds / Q000008:administration & dosage* / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D010880:Piperidines / Q000008:administration & dosage* / Q000494:pharmacology*; D016760:Proto-Oncogene Proteins c-fos / Q000037:antagonists & inhibitors / Q000378:metabolism; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors*; D013312:Stress, Physiological / Q000187:drug effects*
chemical_list: D008782:Methylurea Compounds; D010880:Piperidines; D016760:Proto-Oncogene Proteins c-fos; D018039:Receptors, Tachykinin; C468909:SSR 146977; C103788:3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine